Grand Capital (AGII.US) officially withdraws its application for IPO in the United States, previously planning to raise $9 million.
Grand Holding (AGII.US) has cancelled its plans for an initial public offering (IPO).
The Chinese office space operation service platform Tang Tang Jia (AGII.US) has cancelled its plans for an initial public offering (IPO). The company originally submitted an application in September 2022, and recently planned to issue 1.4 million shares at a price of $6 to $7 per share, raising $9 million.
This is Tang Tang Jia's second attempt at going public. The company had signed a merger agreement with the Special Purpose Acquisition Company (SPAC) Goldenbridge Acquisition in 2021, but the deal was terminated in 2022.
Founded in Shanghai in 2015, Tang Tang Jia was formerly known as Distrii Office. In 2021, the Distrii Office brand was officially rebranded as "AgiiPlus Tang Tang Jia," positioning itself as a leader in "agile office one-stop solution."
The company reported $45 million in revenue for the 12 months ending on December 31, 2023. The company had originally planned to list on the NASDAQ under the symbol "AGII." Kingswood Capital Markets was the sole bookrunner for the transaction.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025